Elranatamab Fixed Dosing: A Safe, Effective, and Convenient Dosing Approach.

Area of Science:

• Oncology
• Immunotherapy

Background:

• Bispecific T-cell engagers (TCEs) represent a promising cancer treatment modality.
• Elranatamab, a bispecific TCE targeting BCMA and CD3, is approved for relapsed or refractory multiple myeloma (RRMM).
• Evaluating dosing strategies, including fixed versus weight-based dosing, is crucial for optimizing TCE therapy.

Purpose of the Study:

• To assess the influence of patient body weight on the pharmacokinetics (PK), safety, and efficacy of elranatamab.
• To determine if body weight impacts elranatamab's therapeutic profile in patients with RRMM.

Main Methods:

• Analysis of data from the phase 2 MagnetisMM-3 trial (NCT04649359).
• Evaluation of PK, safety, and efficacy of elranatamab across different body weight quartiles.
• Patients received a fixed 76-mg subcutaneous dose of elranatamab weekly after priming.

Main Results:

• Elranatamab fixed dosing demonstrated overlapping PK predose concentrations across body weight quartiles, with no clinically relevant differences.
• Safety profiles were comparable across all body weight quartiles.
• Efficacy, including overall response and complete response rates, was consistent across body weight quartiles, with no identified trends impacting progression-free survival or duration of response.

Conclusions:

• Fixed dosing of elranatamab is effective and well-tolerated across a wide range of body weights in RRMM patients.
• Body weight does not significantly impact elranatamab's PK, safety, or efficacy.
• These findings support the current approved fixed dosing regimen for elranatamab.